1. Home
  2. BELFB vs PHVS Comparison

BELFB vs PHVS Comparison

Compare BELFB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bel Fuse Inc. Class B

BELFB

Bel Fuse Inc. Class B

HOLD

Current Price

$319.68

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.39

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BELFB
PHVS
Founded
1949
2015
Country
United States
Switzerland
Employees
4964
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BELFB
PHVS
Price
$319.68
$34.39
Analyst Decision
Strong Buy
Buy
Analyst Count
4
11
Target Price
$174.25
$41.82
AVG Volume (30 Days)
282.7K
414.6K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
0.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.74
N/A
Revenue Next Year
$6.34
N/A
P/E Ratio
$42.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$95.45
$17.70
52 Week High
$335.29
$35.91

Technical Indicators

Market Signals
Indicator
BELFB
PHVS
Relative Strength Index (RSI) 59.72 61.73
Support Level $249.11 $24.73
Resistance Level N/A N/A
Average True Range (ATR) 16.41 1.61
MACD 2.36 0.15
Stochastic Oscillator 67.13 63.99

Price Performance

Historical Comparison
BELFB
PHVS

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: